The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study.

OBJECTIVE In the cortex of animals, serotonin (5-HT) levels increase after several weeks of treatment with selective serotonin reuptake inhibitors (SSRIs). Studies using an intrasubject design to examine the effects of SSRI treatment on 5-HT(2A) receptors in the cortex of drug-free depressed patients are needed. In theory, agonist stimulation of 5-HT(2A) receptors could be relevant to SSRI treatment by promoting neuronal growth and survival as well as direct elevation of mood. The objective of this study was to evaluate the effect of 6 weeks of paroxetine treatment on 5-HT(2A) receptors in depressed patients. METHOD After a medication-free period of at least 3 months, 19 depressed patients were treated for 6 weeks with paroxetine, 20 mg/day. The authors used [(18)F]setoperone and positron emission tomography to assess 5-HT(2A) receptor binding potential in the patients before and after treatment and in 19 age-matched healthy subjects. RESULTS 5-HT(2A) binding potential declined with age in all cortical regions in the depressed and healthy subjects. There was a significant interaction between age and treatment effect on 5-HT(2A) binding potential in all cortical regions. Subjects aged 20 to 30 years had a 10% decrease in 5-HT(2A) binding potential after treatment, whereas subjects aged 30 to 40 had no change. No regional differences in 5-HT(2A) binding potential between depressed and healthy subjects were found. CONCLUSIONS 5-HT(2A) receptors down-regulate in young depressed subjects after treatment with paroxetine, but this down-regulation attenuates with age. This suggests that over 6 weeks paroxetine treatment increases 5-HT agonism on 5-HT(2A) receptors in the cortex of young patients with depression.

[1]  Karl J. Friston,et al.  Assessing the significance of focal activations using their spatial extent , 1994, Human brain mapping.

[2]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[3]  D L Hill,et al.  Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. , 1997, Medical physics.

[4]  E. Nestler,et al.  A molecular and cellular theory of depression. , 1997, Archives of general psychiatry.

[5]  Zhiyuan Ma,et al.  Differential regulation of 5‐hydroxytryptamine release by GABAA and GABAB receptors in midbrain raphe nuclei and forebrain of rats , 1996, British journal of pharmacology.

[6]  F. Artigas,et al.  Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. , 1992, European journal of pharmacology.

[7]  T. Dawson,et al.  Receptor alterations associated with serotonergic agents: an autoradiographic analysis. , 1987, The Journal of clinical psychiatry.

[8]  J. Maloteaux,et al.  Characterization and regional distribution of serotonin S2-receptors in human brain , 1983, Brain Research.

[9]  S. Kapur,et al.  Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging. , 1997, Nuclear medicine communications.

[10]  C Crouzel,et al.  A Method for the In Vivo Investigation of the Serotonergic 5‐HT2 Receptors in the Human Cerebral Cortex Using Positron Emission Tomography and 18F‐Labeled Setoperone , 1990, Journal of neurochemistry.

[11]  C Crouzel,et al.  [18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. , 1988, European journal of pharmacology.

[12]  E. Corruble,et al.  Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors , 1997, Psychopharmacology.

[13]  P. Hrdina,et al.  Chronic fluoxetine treatment upregulates 5‐HT uptake sites and 5‐HT2 receptors in rat brain: An autoradiographic study , 1993, Synapse.

[14]  C. Montigny,et al.  Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  S. Snyder,et al.  2,5-Dimethoxy-4-methyl-amphetamine (STP): A New Hallucinogenic Drug , 1967, Science.

[16]  H. Saito,et al.  Effects of conditioned fear stress on 5-HT release in the rat prefrontal cortex , 1995, Pharmacology Biochemistry and Behavior.

[17]  B. Roth,et al.  5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. , 1998, Pharmacology & therapeutics.

[18]  M. Fillenz,et al.  Both systemic and local administration of benzodiazepine agonists inhibit the in vivo release of 5-HT from ventral hippocampus , 1989, Neuropharmacology.

[19]  J. Baron,et al.  Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  J. Leysen,et al.  5‐HT2 Receptors, Roles and Regulation , 1990, Annals of the New York Academy of Sciences.

[21]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[22]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[23]  A. Ravindran,et al.  Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment , 1997, Psychiatry Research.

[24]  S. Tang,et al.  Manipulations of synaptic serotonin: discrepancy of effects on serotonin S1 and S2 sites. , 1983, Life sciences.

[25]  S H Snyder,et al.  Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. , 1980, Science.

[26]  S. Kapur,et al.  The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET , 1999, Psychopharmacology.

[27]  Anat Biegon,et al.  Autoradiographic analysis of [3H]ketanserin binding in the human brain postmortem: effect of suicide , 1990, Brain Research.

[28]  S. Snyder,et al.  DOM (STP), a new hallucinogenic drug, and DOET: effects in normal subjects. , 1968, The American journal of psychiatry.

[29]  P S Goldman-Rakic,et al.  5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C Crouzel,et al.  Synthesis, affinity and specificity of 18F-setoperone, a potential ligand for in-vivo imaging of cortical serotonin receptors. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[31]  G. Aghajanian,et al.  5-HT2A Receptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex , 1997, The Journal of Neuroscience.

[32]  F. Artigas,et al.  Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei , 1993, Synapse.

[33]  J. Marcusson,et al.  Effect of aging in human cortical pre- and postsynaptic serotonin binding sites , 1993, Brain Research.

[34]  N. Alpert,et al.  Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. , 1996, The Journal of pharmacology and experimental therapeutics.

[35]  E. Azmitia,et al.  The primate serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. , 1986, Advances in neurology.

[36]  S. Kapur,et al.  Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects. , 1999, The American journal of psychiatry.

[37]  Frank Roels,et al.  Autoradiographic localization of D1 and D2 dopamine receptors in the human brain , 1988, Neuroscience Letters.

[38]  J. Leysen,et al.  Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment. , 1989, European journal of pharmacology.

[39]  Ralph Myers,et al.  Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.

[40]  S. Maayani,et al.  Interactions between Effectors Linked to Serotonin Receptors , 1998, Annals of the New York Academy of Sciences.

[41]  Donatella Marazziti,et al.  Distribution and characterization of [3H]mesulergine binding in human brain postmortem , 1999, European Neuropsychopharmacology.

[42]  N. Newberry,et al.  Characterisation of Human 5‐Hydroxytryptamine2A and 5‐Hydroxytryptamine2C Receptors Expressed in the Human Neuroblastoma Cell Line SH‐SY5Y: Comparative Stimulation by Hallucinogenic Drugs , 1996, Journal of neurochemistry.

[43]  Blood–Cerebrospinal Fluid and Blood‐Brain Barriers Imaged by 18F‐Labeled Metabolites of 18F‐Setoperone Studied in Humans Using Positron Emission Tomography , 1992, Journal of neurochemistry.

[44]  P. Liddle,et al.  Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. , 1999, Archives of general psychiatry.

[45]  S. Kapur,et al.  Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. , 1999, The American journal of psychiatry.

[46]  Karl J. Friston,et al.  Spatial registration and normalization of images , 1995 .